Tag: Mirvetuximab soravtansine

This year, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will feature a breadth of new data on emerging antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), particularly across solid tumors and hematologic malignancies. This article synthesizes pivotal findings from AbbVie’s next-generation ADC and TCE platforms—including SEZ6-, PSMA/STEAP1-, c-Met-, and FRα-targeted ADCs—alongside immune checkpoint inhibitor combinations and real-world evidence.

AbbVie Showcases Promising Phase 2 Data for Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer at SGO 2026

Economy: Failure to Reshore Pharmaceutical Manufacturing: US Approved Drug Manufacturing Shifts to Europe as US Deal Volume Drops

Positive early clinical data from the NAPISTAR1-01 Phase 2/2a study (NCT06303505) investigating TUB-040, an antibody-drug conjugates (ADC) being developed by Tubulis, were presented in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress, held October 17 - 21, 2025 in Berlin, Germany.[1] (see ADC Drugmap).

The final analysis of the confirmatory Phase 3 MIRASOL trial (NCT04209855) evaluating the efficacy and safety of mirvetuximab soravtansine (Elahere®; AbbVie - see Drugmap)*...

The European Commission has granted marketing authorization for mirvetuximab soravtansine (Elahere®; AbbVie/ImmunoGen) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

During the upcoming European Society for Medical Oncology (ESMO) Congress being held in Barcelona, September 13-17, 2024, expect presentations to include new data on...

New data from AbbVie's innovative antibody-drug conjugate (ADC) platform will be showcased across three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024).

At the recently held annual meeting of the American Association for Cancer Research (AACR), positive Phase 2 trial (NCT03835819) results of the combination of mirvetuximab soravtansine and the immune checkpoint inhibitor (ICI) Pembrolizumab (Keytruda®; Merck & Co) in the treatment of folate receptor-alpha (FR-α) positive recurrent microsatellite stable / mismatch repair proficient serous endometrial cancer were presented.

Mirvetuximab soravtansine Receives full FDA approval for use in treatment of Certain Ovarian Cancer Patients